Companies › iOnctura
1 active drug program in 7 registered trials: 6 Phase 1, 1 Phase 2; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| roginolisib (IOA-244) PI3K inhibitor | PIK3CA | Phase 2 | Uveal Melanoma; Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Myelofibrosis (MF); Solid Tumor, Adult … | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06879717 | roginolisib (IOA-244) | Phase 1 | Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Oncology | Jan 2027 |
| NCT07203391 | roginolisib (IOA-244) | Phase 1 | Uveal Melanoma, Metastatic | Oncology | Dec 2027 |
| NCT06717126 | roginolisib (IOA-244) | Phase 2 | Uveal Melanoma | Oncology | Dec 2027 |
| NCT06887803 | roginolisib (IOA-244) | Phase 1 | Myelofibrosis (MF) | Oncology | Mar 2028 |
| NCT04328844 | roginolisib (IOA-244) | Phase 1 | Solid Tumor, Adult | Oncology | Mar 2028 |
| NCT07018752 | roginolisib (IOA-244) | Phase 1 | Peripheral T Cells Lymphoma (PTCL) | Oncology | Apr 2028 |
| NCT06644183 | roginolisib (IOA-244) | Phase 1 | Leukemia | Oncology | Oct 2028 |
Risen (Suzhou) Pharma Tech Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.